Validation of the DCTclock drawing task as a cognitive screening tool for prodromal Alzheimers disease in the Framingham Heart Study

在弗雷明汉心脏研究中验证 DCTclock 绘图任务作为前驱阿尔茨海默病的认知筛查工具

• 批准号: 10490305
• 负责人: Louisa Thompson
• 金额: $ 16.07万
• 依托单位: BROWN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-30 至 2023-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10490305
• 关键词: Address; Administrator; Adult; Alzheimer' s Disease; Alzheimer' s disease pathology; Alzheimer' s disease related dementia; Alzheimer' s disease risk; Alzheimer’s disease biomarker; Amyloid; Amyloid beta-Protein; Behavior; Biological Markers; Brain; Cerebrum; Clinic; Clinical Research; Clinical Trials; Cognition; Cognitive; Cohort Studies; Communities; Computer software; Data; Databases; Dementia; Detection; Development; Diagnosis; Disease; Disease susceptibility; Early Diagnosis; Elderly; FDA approved; Foundations; Framingham Heart Study; Funding; Future; Genetic Markers; Genetic Risk; Genotype; Goals; Health Professional; Hippocampus (Brain); Hospitals; Impaired cognition; Individual; Infarction; Intervention; Journals; Liquid substance; Machine Learning; Magnetic Resonance Imaging; Massachusetts; Measures; Medicare; Methods; Monitor; Neuropsychological Tests; Neuropsychology; Organizational Decision Making; Parietal; Participant; Patients; Peer Review; Performance; Persons; Population; Positron-Emission Tomography; Prevention Research; Primary Health Care; Publishing; Research; Risk; Sample Size; Sampling; Screening procedure; Secure; Statutes and Laws; Technology; Testing; Thick; Time; Validation; White Matter Hyperintensity; Work; abeta deposition; amnestic mild cognitive impairment; base; cerebrovascular; clinical care; cognitive change; cognitive testing; cost; cost effective; digital; genome wide association study; gray matter; health disparity; imaging biomarker; improved; indexing; medical specialties; mental state; mild cognitive impairment; multimodality; neuroimaging; neuroimaging marker; neuropathology; normal aging; patient screening; primary care setting; processing speed; prodromal Alzheimer' s disease; prognostic; prospective; recruit; screening; socioeconomics; validation studies; β-amyloid burden

Abstract. The diagnosis of probable Alzheimer’s disease (AD) has traditionally depended on fluid biomarkers and neuroimaging. However, these tests are often invasive, expensive, and generally available only in specialty clinics. Common neuropsychological tests used to screen for dementia (e.g., Mini-Mental State Examination) are not sensitive enough to detect early cognitive changes that can predict the emergence of prodromal AD. The DCTclockTM is an FDA approved digital neuropsychological test with the potential to be deployed in primary care and clinical trials research as a non-invasive and cost-effective screening tool for detecting the earliest stages of AD. The DCTclockTM can be easily administered by any healthcare professional and uses cutting-edge methods to capture nuanced neuropsychological behavior. Initial studies suggest that the DCTclockTM has high sensitivity to predict cortical amyloid (Aß) deposition and parietal hypometabolism on neuroimaging, suggesting that it could serve as a surrogate for more invasive or costly biomarker testing. This project will validate the DCTclockTM in a large sample of older adults from the Framingham Heart Study (FHS), using cross sectional and longitudinal approaches with the goals of determining: (1) the DCTclock’s ability to distinguishing mild cognitive impairment (MCI) from normal aging relative to existing cognitive screening measures, (2) its associations with genetic biomarkers of AD and neuroimaging measures of AD pathology, including MRI metrics and brain Aß levels on a PET scan. DCTclockTM drawing data has been collected in the FHS since 2011 from over 1,600 older adults without dementia, making it an ideal database for this validation study.

摘要。诊断可能的阿尔茨海默病（AD）传统上依赖于液体生物标志物